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patient as a weighted score of the patient’s total comorbid condi-
tions. Results: Median age was 37 years (17-67). There were 43
males  35 females. Conditioning was with Thiotepa/Busulfan
(Bu)/Cytoxan (Cy), Decitabine/Bu/Cy or Bu/Cy in 18 patients,
Fludarabine (Flu)/Melphalan in 9 patients, Flu/Ara-C/Idarubicin
in 9 patients, Flu/Bu in 7 and TBI based regimen in 35 patients.
Sixty-four patients received stem cells from a sibling donor and 14
from other related or unrelated donors. Analysis was performed
comparing patients with a CCI score of 0-2 with patients who had
a score2. These groups were also compared for patients who had
age as comorbidity and for patients who did not (age  40 yrs).
Univariate analysis showed that patients with CCI score of 0-2 had
a better overall and event free survival (OS/EFS) than patients who
had CCI score 2 (Table 1). CCI score 2 was also predictive of
non-relapse mortality (NRM). Moreover, CCI score was a stron-
ger predictor of OS, EFS and NRM in patients aged 40 years.
Conclusions: These results demonstrate the relevance of a stan-
dardized comorbidity score in predicting transplant outcomes in a
relatively homogenous population. Our analysis indicates that CCI
score can segregate patients into low or high risk for NRM and is
predictive of OS and EFS in AML/MDS patients who received an
allogeneic HSCT in 1st CR.
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STEM CELL TRANSPLANTATION FOR FANCONI ANEMIA: 20 YEARS OF
PROGRESSIVE DECREASE IN THE DOSE OF CYCLOPHOSPHAMIDE
WITHOUT IRRADIATION
Zanis Neto, J.1, Bitencourt, M.A.1, Bonﬁm, C.M.S.1, Medeiros, C.R.1,
Moreira, V.A.1, Setubal, D.C.1, Flowers, M.E.D.2, Pasquini, R.1 1.
Federal University of Parana, Curitiba, PR, Brazil; 2. Clinical Research
Division, Fred Hutchinson Cancer Research Center, Seattle, WA
Introduction: Alkylating agents and irradiation have been uti-
lized as conditioning regimen for BMT in Fanconi Anemia (FA)
for many years. FA patients (pts) are particularly hypersensitive to
these agents and its toxicity is the main cause of mortality and
morbidity after transplant. In order to decrease toxicity and main-
tain engraftment we have progressively decreased the dose of
Cyclophosphamide (CY) during the past 20 years. Material and
methods: Between 11/83 and 06/03 our BMT Unit transplanted
120 FA pts. In this study we select only pts in aplastic phase,
without myelodysplastic syndrome or leukemia. The CY doses
divided in four days were: 200 mg/kg: 10 pts; 140 mg/kg: 13 pts (8
pts received ATG 90 mg/kg or lymphoglobuline or thymoglobulin
in equivalent dose); 120 mg/kg: 8 pts; 100 mg/kg: 19 pts; 80 mg/kg:
7 pts and 60 mg/kg: 23 pts. Two pts were transplanted at the Fred
Hutchinson Cancer Research Center in Seattle (80 mg/kg: 1pt and
60 mg/kg: 1pt). All donors were full compatible HLA siblings
except in the CY60 group where there were two different full
compatible donors: a grandfather and an uncle. All pts received
cyclosporine (Csa) and methotrexate (Mtx) as GVHD immunepro-
phylaxis and prophylactic antibiotics: ﬂuconazol, sulfamethox-
azole-trimethoprim and acyclovir according to common practice.
Results: See table for pts characteristics, disease duration, previous
blood transfusions, GVHD incidence and overall survival. Chimer-
ism studies: all survivors have complete blood counts recovery to
normal values except for one pt in the CY60 group who was heavily
transfused before BMT (100 transfusions). She is now outpatient
but transfusion dependant and the VNTR shows 45% of donor
cells. Another pt in the CY60 had a late rejection (donor: grand-
father) and underwent a second transplant. He is currently alive
and well with 100% of donor cells and normal hematological
counts one year after this transplant. Conclusion: Decreasing the
dose of CY to 60mg/kg has led to a better survival, less toxicity, no
transplant related mortality and low incidence of both acute and
chronic GVHD.
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SERIOUS COMPLICATIONS FOLLOWING UNRELATED DONOR MARROW
COLLECTION: EXPERIENCES OF THE NATIONAL MARROW DONOR
PROGRAM
Confer, D.L.1, Leitman, S.F.2, Papadopoulos, E.B.3, Price, T.H.4,
Stroncek, D.F.2, Robinett, P.1, Braem, B.1, Gandham, S.1 1. National
Marrow Donor Program, Minneapolis, MN; 2. National Institutes of
Health-Transfusion Medicine, Bethesda, MD; 3. Memorial Sloan-Ket-
tering Cancer Center, New York, NY; 4. Puget Sound Blood Center,
Seattle, WA
National Marrow Donor Program®(NMDP) marrow collec-
tions between December 1987 and December 1999 (n  9282)
were evaluated to identify serious complications. Using data from
standardized individual follow-up forms, a panel of ﬁve physicians
reviewed 345 cases with potentially serious medical complications
(e.g. excessive pain, adverse acute anesthesia reactions, delayed
return to normal activities or the need for additional medical
intervention) and by consensus identiﬁed 125 (1.35% of the 9282
total) serious complications. Of the 125 serious cases, proximal
cause fell into ﬁve categories: (1) mechanical injury to tissue, bone,
or nerve (n  69, or 55% of serious subset and 0.7% of total); (2)
anesthesia (n  45, or 36% of serious subset and 0.5% of total); (3)
infection (n  1, or 0.8% of serious subset and 0.01% of total); (4)
other (n  1 [grand mal seizure], or 0.8% of serious subset and
0.01% of total); and (5) serious events thought to be unrelated to
donation (n  9 [6 cases of cancer and 3 cases of herniated spinal
disk requiring major interventions], or 7% of serious subset and
0.09% of total). The 116 donors with complications directly re-
lated to donation were further characterized according to symptom
nature and duration. Sixty-seven donors (58% and 0.7% of total)
experienced prolonged recovery periods (from months to years).
Forty-nine donors (42% and 0.5% of total) experienced severe
acute reactions, mostly related to anesthesia . Univariate and mul-
tivariate analysis indicated regional anesthesia, longer duration of
collection, female gender, and older age as signiﬁcant donor char-
acteristics for risk of serious complication. In conclusion, the in-
cidence of serious complications from marrow donation is low
(1.35%) and mechanical injury was the most frequent cause of
prolonged post collection recovery. The risks of marrow collection
Table. Effect of Comorbidity Scores on Allogeneic Transplant
Outcomes in AML/MDS Patients
Outcomes for all
patients
CCI Score 0-2
(N  28)
CCI Score >2
(N  50) P value
% OS @ 2 yrs. 83 53 0.001
% EFS @ 2 yrs. 76 38 0.0004
% NRM Day100 3 14 0.02
% NRM Day360 4 26 0.02
Outcomes for pts
<40 yrs old
CCI Score 0-2
(N  24)
CCI Score >2
(N  21) P value
% OS @ 2 yrs. 91 45 0.0009
% EFS @ 2 yrs. 83 32 0.0008
% NRM Day100 0 25 0.005
% NRM Day360 0 25 0.005
Table. Decreasing Doses of Cy for FA patients
Cy 200 Cy 140 Cy 120 Cy 100 Cy 80 Cy 60
# patients 10 13 8 19 7 23
Age-yr.-M
(range) 13 (5-32) 8 (3-30) 9 (6-19) 8 (3-22) 9 (5-16) 9 (5-29)
# previous
transf.-U-M
(range) 21 (2-151) 6 (0-200) 5 (0-100) 8 (0-100) 4 (0-50) 6 (0-101)
Disease dur.-m-
M (range) 35 (1-105) 12 (4-58) 13 (7-89) 16 (4-159) 28 (21-72) 35 (1-124)
# of MTX doses
for GVHD
prophylaxis 3 (2-4) 0 (0-4) 3 (0-4) 3 (2-4) 4 (3-4) 3 (3-4)
GVHD a III-IV
% 12.5 17 0 0 28.5 4
GVHD c
extensive % 33 27 20 12.5 33 4
Survival % 30 69 50 79 57 100
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should be compared with G-CSF mobilized peripheral blood stem
cell collection.
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NEUTROPENIA AND THROMBOCYTOPENIA INDUCED BY G-CSF ADMIN-
ISTRATION IN HEALTHY PBSC ALLOGENEIC DONORS: HOW LONG
SHOULD BE PROLONGED HEMATOLOGICAL AND CLINICAL SURVEIL-
LANCE?
Tassi, C., Anna, N., Valeria, G., Roberto, C. Medical Transfusion
Service-Sant’orsola, Bologna, Bologna, Italy
From February 1998, one hundred and twenty peripheral blood
stem cell (PBSC) healthy donors were treated with G-CSF for 4-7
days and submitted to leukoapheresis courses in the Apheresis Unit
of our Service. All were enrolled on short and long-term clinical
and hematological surveillance protocol for a ﬁve year time. To-
date, 95 donors are evaluable: overall mean follow-up time is 31
months, being 36 months in 45 and 12 months in 13 subjects.
Main clinical adverse effects to Lenograstim were headhache
(65%), musculo-skeletal pain (78%) and fatigue (69%); no therapy
or low paracetamol doses were employed in 95% of the donors.
Pre-leukoapheresis mean platelet reduction was assessed at 23.6%
 9% and detected in 42/95 cases; an additional decrease of
absolute WBC counts, in particular due to both PMN and Lym-
phocyte low numbers, was diagnosed in 27 subjects of this group.
Pre-G-CSF administration platelet values were observed at 12
months of follow-up. Multivariate and univariate analysis demon-
strated a correlation between duration of G-CSF administration
(p.004), pre G-CSF platelet level (p.003) and decreased platelet
count before leukoapheresis. At this regard, PMN and or lympho-
cyte lower values were counted in 75 out of 95 donors two weeks
after G-CSF administration, whereas PMN and Lymphocytes
were signiﬁcantly decreased in 43 out of the 75 subjects (-39.3%
and -30%, respectively). Transient PMN count below 1000/ul was
detected in 4/43 cases. Finally, in 12/43 donors pre mobilization
number of PMNs or Lymphocytes were reached only after 24
months of follow-up time. Univariate and multivariate analysis
demonstrated strict correlation between-n reduction at 4, 8,
and 12 months of follow-up, and G-CSF administration days
(p.0021)  pre-mobilization PMN absolute counts (p.003). Sex
and age of patients did not signiﬁcantly correlate with WBC
decremental trend; however, isolated PMN low values were more
frequently observed in young patients, since in this group mean age
was 38.5  15 yrs in comparison to lymphocytopenic donors
(44.7 5 yrs). Taken altogether, these results seem to demonstrate
in younger PBSC donors treated with G-CSF for more than ﬁve
days, negative effects on myelopoiesis lasting two years, without
any ﬁndings of haematological disorders or clinical sign of disease.
In these limited cases, a hematocromocytometric observation may
be prudentially prolonged over ﬁve years.
AUTOLOGOUS
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PEGFILGRASTIM (NEULASTA) FOLLOWING CHEMOTHERAPY LEADS
TO SUCCESSFUL MOBILIZATION OF HEMATOPOIETIC PROGENITOR
CELLS AMONG TRANSPLANT PATIENTS WITH VARIOUS DIAGNOSES
Mandanas, R.A.1, Underwood, B.J.1, Geister, B.V.1, Smith, J.W.2 1.
Western Oklahoma Blood and Marrow Transplant Program, Cancer
Care Associates, Oklahoma City, OK;2. Oklahoma Blood Institute, Okla-
homa City, OK
Filgrastim has been traditionally used following chemotherapy to
mobilize hematopoietic progenitor cells. Doses of 5-10 g/kg/day
subcutaneously have been given until recovery of WBC counts to
over 5.0  103/L before initiating leukapheresis. Pegﬁlgrastim
(Neulasta™) produced by covalently binding a 20-kd monome-
thoxypolyethylene glycol molecule to the N-terminal methionyl
residue of ﬁlgrastim has a much longer half-life allowing for a
single 6 mg subcutaneous injection with similar efﬁcacy and safety
proﬁle as ﬁlgrastim in reducing the duration of severe chemother-
apy-induced neutropenia. Thirteen patients with various diagnoses
(6 Myeloma, 4 NHL, 1 breast cancer, 1 seminoma, 1 CLL) re-
ceived pegﬁlgrastim 6 mg single injection 1 day after completing
mobilization chemotherapy (cytoxanetoposide  8; cytoxan  2;
ICE  Rituximab  2; taxotereadriamycincytoxan  1). The
median age was 56 years (28-71) with 8 females and 5 males.
Leukapheresis processing 3 times the estimated blood volume was
initiated beginning recovery of total WBC count to at least 5.0 
103/L. The minimum target of 2.5  106/kg CD34 cell count
was achieved 100% in all 13 patients after only one day of leuka-
pheresis. The optimal target of 5.0  106/kg CD 34 cell count
was obtained in 85% (11/13 patients) in a single day of collection.
The mean CD34 cell count collected in the ﬁrst day was 16.8 
106/kg (median 13.6, range 2.5 – 45.5). Two patients (1 CLL, 1
Myeloma with CLL) had their harvested product CD34-selected
before cryopreservation. All patients engrafted following their au-
totransplants. Engraftment data were as predicted for peripheral
blood stem cell recovery times (Time to ANC of 500/L: mean
10.3 days, range 8-11 and time to Platelet count 20  103/L:
mean 11.5 days, range 9-15). In conclusion, pegﬁlgrastim given as
a single 6 mg subcutaneous injection after chemotherapy is a viable
alternative to multiple daily injections of ﬁlgrastim for the mobi-
lization of hematopoiteic progenitor cells.
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PERIPHERAL BLOOD STEM CELL TRANSPLANT (PBSCT) IN A LARGE
SERIES OF PATIENTS WITH POEMS SYNDROME
Dispenzieri, A.1, Moreno-Aspitia, A.2, Lacy, M.Q.1, Colon-Otero, G.2,
Tefferi, A.1, Litzow, M.R.1, Gertz, M.A.2 1. Mayo Clinic, Rochester,
MN; 2. Mayo Clinic, Jacksonville, FL
Background: The POEMS syndrome is characterized by pe-
ripheral neuropathy (PN), clonal plasma cell disorder (PCD), or-
ganomegaly, endocrinopathy, skin changes, edema, sclerotic bone
lesions, and thrombocytosis. Based on the improved response rates
observed with PBSCT in patients with other PCD, autologous
Table. Summary of Serious Marrow Complications
3
Symptom
Nature/
Duration
2Proximal
Cause
Acute/
Atypical
Acute/
Known Cancer
Herniated
Disk
Prolonged
Recovery/
Mild
Prolonged
Recovery/
Moderate-
Severe Total
Anesthesia 15
(75%)
28
(97%)
0 0 2
(7%)
0 45
(36%)
Infection 1 (5%) 0 0 0 0 0 1
(1%)
Mechanical
Injury
4 (20%) 0 0 0 25
(93%)
40
(100%)
69
(55%)
Unrelated/
Other
0 1
(3%)
6
(100%)
3
(100%)
0 0 10
(8%)
Total 20 29 6 3 27 40 125
Table. Variation of PMN in 24 Months of Follow-up Time
T0 PMN
counts
%
Decre-
ment
 14
%
Decre-
ment
 4m
%
Decre-
ment
 8m
%
Decre-
ment
 12m
%
Decre-
ment
 24m
10 Patients
lymphopenic 3310  320
not
change
not
change
not
change
not
change
not
change
22 Patients
neutropenic 4450  1220 37.5  13.9 12  5 8  3 9  3.5 12.4  4
43 Patients ly
 neutro-
penic  3855  456 39.5  14 15  3.7 10  2.8 13  6 21.6  9
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